What's Happening?
A recent study published in JAMA reveals a significant increase in GLP-1 medication prescriptions among privately insured new mothers in the United States. The share of women initiating GLP-1 drugs, such as Ozempic or Zepbound, within six months of delivery
rose from 0.08% in the first half of 2018 to 1.9% in the first quarter of 2025, marking a nearly 24-fold increase. This analysis, led by Sih-Ting Cai of the Schaeffer Center and co-authors from Indiana University, reviewed insurance claims covering over one million births. The steepest rise was observed in women with type 2 diabetes, with prescriptions climbing from 2.3% to 16.9% by early 2025. Women with a history of gestational diabetes also saw an increase from 0.4% to 2.7%, while those with diagnosed obesity or overweight experienced the fastest relative growth, from 0.4% to 3.9%. The study notes that most women started these medications at least three months postpartum, and patients are advised to discontinue GLP-1 drugs during pregnancy.
Why It's Important?
This surge in postpartum GLP-1 prescriptions highlights a growing trend in managing metabolic risks after pregnancy, but it also brings to light critical concerns regarding safety, particularly for breastfeeding infants. The study, while tracking prescription patterns, did not evaluate the drugs' efficacy, side effects, or impact on babies. This lack of comprehensive safety data for nursing infants creates a dilemma for new mothers who are often navigating sleep deprivation, infant feeding, and personal health decisions simultaneously. The National Library of Medicine's LactMed database offers some early data suggesting that injectable semaglutide and tirzepatide (at doses up to 5 mg) are generally not detectable in breast milk, but emphasizes the need for more extensive research, especially concerning newborns and preterm infants. The cost of these medications and varying insurance coverage for weight management also present significant barriers, disproportionately affecting lower-income mothers, as the study excluded those on Medicaid.
What's Next?
The findings underscore the urgent need for further research into the safety and long-term effects of GLP-1 medications on breastfeeding mothers and their infants. Medical professionals will likely face increased questions from new mothers considering or already taking these drugs. Current medical guidance advises new mothers to consult with their obstetrician, primary care clinician, or endocrinologist before starting, stopping, or changing any medication, discussing factors like breastfeeding plans, nutritional needs during recovery, birth control, and insurance coverage. Pediatricians and lactation consultants may also become more involved in monitoring infants for any potential changes in feeding or growth. The study's lead author, Sih-Ting Cai, explicitly stated that the rising postpartum initiation of GLP-1s warrants further study due to limited evidence on GLP-1 exposure during breastfeeding. This will likely prompt pharmaceutical companies and research institutions to conduct larger, more definitive studies to provide clearer guidelines for this vulnerable population.
Beyond the Headlines
The increasing use of GLP-1 drugs postpartum reflects a broader societal shift towards medical interventions for weight management and metabolic health, even in sensitive periods like early motherhood. This trend raises ethical considerations about the balance between maternal health and infant safety, especially when comprehensive data are still emerging. The exclusion of Medicaid patients from the study also points to potential disparities in access to and information about these medications, highlighting a need for equitable healthcare policies. Furthermore, the emphasis on 'bouncing back' after childbirth, often fueled by societal pressures, might contribute to the demand for rapid weight loss solutions, potentially influencing medical decisions without full understanding of long-term consequences. The disclosure of a conflict of interest by the lead author, whose immediate family member is employed by a GLP-1 manufacturer, also subtly underscores the complex interplay between research, pharmaceutical interests, and public health recommendations.
